PSMA Theranostic Kits Market Developments Driving Growth
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2026 And 2030?
The market size for prostate-specific membrane antigen (psma) theranostic kits has experienced rapid expansion in recent years. This market is anticipated to climb from $1.05 billion in 2025 to $1.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.9%. The historical growth trajectory can be attributed to several factors including the rising incidence of prostate cancer, notable advancements in nuclear medicine imaging, an increasing embrace of molecular diagnostics, the early successful clinical validation of psma targeting methods, and the ongoing expansion of oncology research programs.
The market for prostate-specific membrane antigen (psma) theranostic kits is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $1.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This projected growth during the forecast period can be attributed to several factors, including a heightened demand for customized cancer therapies, increased capital expenditure in theranostics, the expansion of nuclear medicine facilities, the expanding application of precision oncology diagnostics, and a rise in regulatory clearances for specific therapies. Key developments expected during the forecast period encompass a greater acceptance of targeted radioligand treatments, an increase in the utilization of psma-based precision diagnostics, a deeper integration of imaging and therapeutic processes, the proliferation of personalized oncology treatment kits, and a strengthened emphasis on companion diagnostics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30362&type=smp
Which Factors Are Influencing The Growth Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?
An increasing occurrence of prostate cancer is projected to fuel the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market moving ahead. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small gland situated in men beneath the bladder and anterior to the rectum. The growing occurrence of prostate cancer stems from an aging demographic, given that the likelihood of developing this cancer substantially rises with advancing age. Prostate-specific membrane antigen (PSMA) theranostic kits improve prostate cancer management by providing targeted diagnostic options, which makes them highly suitable for prompt detection and customized treatment strategies. These kits boost diagnostic precision through the combination of PSMA-specific ligands and radiotracers, thereby aiding more effective disease tracking and therapeutic direction. For example, in November 2023, estimates from the American Cancer Society, a US-based non-profit organization, indicated approximately 313,780 new prostate cancer cases and 35,770 related deaths were anticipated in the United States by 2025. Consequently, the increasing prevalence of prostate cancer is fueling the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market.
Which Segments Define The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Segment Structure?
The prostate-specific membrane antigen (psma) theranostic kits market covered in this report is segmented –
1) By Product Type: Diagnostic Kits, Therapeutic Kits, Combined Theranostic Kits
2) By Application: Prostate Cancer, Other Cancers
3) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, Liquid Biopsy Kits
2) By Therapeutic Kits: Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, Small Molecule Therapy Kits
3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits, Dual Function Radiopharmaceutical Kits, Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits, Personalized Treatment Kits
Which Trends Are Influencing Demand In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?
Leading companies within the prostate-specific membrane antigen (PSMA) theranostic kits market are concentrating on developing innovative solutions, such as PSMA-targeted radioligand kits, to address the increasing need for precision oncology, targeted prostate cancer diagnosis, and treatment. PSMA-targeted radioligand kits are medical devices that combine a ligand specifically engineered to bind to Prostate-Specific Membrane Antigen (PSMA) with a radioactive isotope, utilized for either diagnostic imaging or focused therapy of prostate cancer. For instance, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an advanced kit designed for the preparation of Gallium-68 gozetotide injection. This kit empowers hospitals and nuclear medicine facilities to label the radionuclide immediately before administration for PET imaging of PSMA-positive prostate cancer lesions. Distinctive features of the kit include a ready-to-use preparation format, disease-specific targeting, rapid imaging capabilities, and compatibility with theranostic workflows, which facilitates improved detection of metastatic lesions, comprehensive treatment planning, and effective monitoring of therapy response. Its applications involve diagnosing recurrent or metastatic prostate cancer and guiding personalized treatment decisions, marking a substantial progression over conventional imaging or non-targeted therapies.
Who Are The Established Players Within The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?
Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics
Get The Full Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report:
Which Region Accounts For The Largest Portion Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?
North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market 2026, By The Business Research Company
Prostate Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report
Prostate Cancer Nuclear Medicine Diagnostics Market Report
Endocrine Peptide Test Market Report
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
